Lumida
/DSGN
⌘K
Design Therapeutics Inc

Design Therapeutics Inc

DSGN
$14.63USD↓-1.15%-0.17 today

MARKET CAP

915.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$14 – $15

52W RANGE

$5
$17

AI Summary

Stalk
Buy NowHigh

In a Stage 2 advancing corrective reset within a broader uptrend, active Lockout Rally dynamics and sustained EMA support justify immediate bullish participation despite overbought readings, focusing on pullbacks into rising EMA confluence near the prior breakout zone.

  • ↑Phase 1 MAD trial raised frataxin mRNA by 30% at 300 mg vs placebo.
  • ↑Ended Q2 2023 with $303 M cash, funding ops through 2026.
  • ↓Earnings yield and profitability scores deeply negative, signaling poor returns.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Design Therapeutics, Inc. (NASDAQ: DSGN) is a biopharmaceutical company at the forefront of genomic medicine, focusing on developing GeneTAC small molecule therapies aimed at addressing inherited nucleotide repeat diseases. With its leading candidate, DT216, targeting Friedreich ataxia, Design Therapeutics sits within the rapidly evolving biotechnology sector, emphasizing innovative approaches to genetic disorders.

Bull says

  • ↑Phase 1 MAD trial raised frataxin mRNA by 30% at 300 mg vs placebo.
  • ↑Ended Q2 2023 with $303 M cash, funding ops through 2026.
  • ↑Analysts rate DSGN a Strong Buy with $25.89 target (+66%).
  • ↑4.6–5.3 M U.S. Friedreich ataxia patients represent large unmet need.
  • ↑Expect improved DT216 formulation Phase I trial in 2H 2024.
  • ↑Strong stock momentum and high institutional ownership bolster sentiment.

Bear says

  • ↓Earnings yield and profitability scores deeply negative, signaling poor returns.
  • ↓Elevated leverage raises financial stability concerns amid rate volatility.
  • ↓Analyst earnings revisions trending downward, showing profit skepticism.
  • ↓DT216 injection-site thrombophlebitis forces reformulation and delays.
  • ↓High clinical execution risk could push approvals beyond forecasts.

Earnings Call · Q2 2023 · Mgmt. Guidance

Updated 08-30-2026neutral

Transcript signals

Bull points

  • So as we look ahead with a formulation that is not limited by injection site tolerability, we can both plan to dose patients both at higher doses if needed and also for longer-term treatment, which is the ultimate goal for treating NFA.
  • And does this really change meaningfully in terms of the R&D spend between now and data in 25?
  • So we ended the quarter with $303 million in cash, and we've updated the guidance to cash through 2026, which enables us to execute on the current operating plan and the upcoming milestones.

Bear points

  • we elected to complete the dose escalation in this phase one study of the 300 milligram cohort due to concern for potential worsening of injection-site thrombophlebitis at higher doses with multiple administrations.
  • we elected to complete the dose escalation in this phase one study of the 300 milligram cohort due to concern for potential worsening of injection-side thrombophlebitis at higher doses with multiple administrations.
  • this hiatus before we can resume clinical development of DT216 is disappointing to the FA community, especially after showing clinical activity in phase one.
Read full transcript analysis ›